Clinically meaningful, durable benefit was observed in the indicated patient population1,4

QUADRA evaluated ZEJULA as treatment in 4th-line+ patients, including those with BRCA− or platinum-resistant disease1

QUADRA: a single-arm, phase 2 trial of patients (N=463) with advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy1,7

BRCA+, breast cancer susceptibility gene mutated; BRCA−, not BRCA mutated; CI, confidence interval; CR, complete response; DOR, duration of response; GIS, genomic instability status; HRD+, homologous recombination deficiency positive; NE, not evaluable; ORR, overall response rate; PARP, poly (ADP-ribose) polymerase; PR, partial response.

References: 1. ZEJULA [package insert]. Waltham, MA: TESARO, Inc.; October 2019. 2. Rubraca (rucaparib) [package insert]. Boulder, CO: Clovis Oncology, Inc; April 2018. 3. Lynparza (olaparib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2019. 4. Moore KN et al. QUADRA: a phase 2, open-label, single-arm study to evaluate niraparib in patients with relapsed ovarian cancer in the 4th or later line of therapy: results from the BRCAmut subset. Poster presented at: European Society for Medical Oncology Annual Meeting; October 19-23, 2018; Munich, Germany. 5. Berek JS et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29(8):1784-1792. 6. Matulonis U et al. Baseline platelet count and body weight as predictors of early dose modification in the QUADRA trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer. Slide deck presented at: 50th Annual Meeting of the Society of Gynecologic Oncology; March 16-19, 2019; Honolulu, HI. 7. Moore KN et al. Lancet Oncol. 2019;20(5):636-648. 

Safety data


Learn about the safety and tolerability of ZEJULA

See Safety
Dosing information


See recommendations for dose adjustments

Review Dosing